Cancer: Biomarkers, the Path from a Molecular Clue to Clinical Application

Authors

DOI:

https://doi.org/10.20983/culcyt.2026.3.5.1

Keywords:

cancer, biomarker, validation

Abstract

Cancer represents a public health concern, accounting for thousands of new cases and deaths; that’s why considerable efforts have been devoted to identifying complementary tools, looking for new procedures and changing the conventional medical evaluation and diagnosis. Biomarkers could be one of these tools and provide valuable information about health or disease status. However, before to the clinical practice, these must be rigorously validated ensuring their accuracy, reproducibility, and reliability.

Downloads

Download data is not yet available.

Author Biographies

Diana Patricia Armenta Calzadillas, Universidad Autónoma de Ciudad Juárez

PhD Student,  Departamento de Ciencias Químico-Biológicas, Instituto de Ciencias Biomédicas, Universidad Autónoma de Ciudad Juárez; Ciudad Juárez, Chihuahua, México

Mauricio Salcedo Vargas, Universidad Autónoma de Ciudad Juárez

Head of the Research Unit in Biomedicine and Genomic Oncology, Hospital de Gineco Pediatria 3A; Ciudad de México, México

Florinda Jiménez Vega, Universidad Autónoma de Ciudad Juárez

Professor-Researcher, Departamento de Ciencias Químico-Biológicas, Instituto de Ciencias Biomédicas, Universidad Autónoma de Ciudad Juárez; Ciudad Juárez, Chihuahua, México

References

World Health Organization, “Global status report on cancer 2026: The future we choose together”, World Health Organization Ginebra, Suiza, 2026. [En línea] Disponible: https://www.who.int/publications/i/item/9789240123977

National Cancer Institute. “Understanding cancer”. Cancer.gov. [En línea]. Disponible: https://www.cancer.gov/about-cancer/understanding

A. B. Chen et al., “Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: A Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study”, J. Clin. Oncol., vol. 31, n.º 5, pp. 558-564, feb. 2013, doi: 10.1200/jco.2012.43.7954.

A. P. S. Sandhu et al., “Decoding cancer risk: Understanding gene-environment interactions in cancer development”, Cureus, vol. 16, n.º 7, art. e64936, jul. 2024, doi: 10.7759/cureus.64936.

S. Das, M. K. Dey, R. Devireddy y M. R. Gartia, “Biomarkers in cancer detection, diagnosis y prognosis”, Sensors, vol. 24, n.º 1, art. 37, 2024, doi: 10.3390/s24010037.

K. Purkayastha et al., “The issues and challenges with cancer biomarkers”, J Cancer Res Ther, vol. 19, supl. 1, pp. S20-S35, 2023, doi: 10.4103/jcrt.jcrt_384_22.

N. H. Esfandari y M. Papaleontiou, “Biochemical testing in thyroid disorders”, Endocrinol Metab Clin North Am, vol. 46, n.º 3, pp. 631-648, sept. 2017, doi: 10.1016/j.ecl.2017.04.002.

D. B. Sacks et al., “Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus”, Diabetes Care, vol. 46, n.º 10, pp. e151-e199, 2023, doi: 10.2337/dci23-0036.

S. A. Butler, S. A. Khanlian y L. A. Cole, “Detection of early pregnancy forms of human chorionic gonadotropin by home pregnancy test devices”, Clinical Chemistry, vol. 47, n.º 12, pp. 2131-2136, 2001, doi: 10.1083/clinchem/47.12.2131.

M.Partidar, S. Agrawal, F. Parveen y P. Khare, “Molecular insights of saliva in solving paternity dispute”, J. Forensic Dent. Sci., vol. 7, n.º 1, pp. 76-79, en.-abr. 2015, doi: 10.4103/0975-1475.150325.

K. C. Wai, M. P. Strohl, A. van Zante y P. K. Ha, “Molecular diagnosis in human papillomavirus-related head and neck squamous cell carcinoma”, Cells, vol. 9, n.º 2, art. 500, feb. 2020, doi: 10.3390/cells9020500.

J. M. Vindeirinho, E. Pinho, N. F. Azevedo y C. Almeida, “SARS-CoV-2 diagnostics based on nucleic acids amplification: From fundamental concepts to applications and beyond”, Front. Cell. Infect. Microbiol., vol. 12, art. 799678, mar. 2022, doi: 10.3389/fcimb.2022.799678.

T. Y. Jin, K. S. Park, S. E. Nam, Y. B. Yoo, W. S. Park y I. J. Yun, “BRCA1/2 serves as a biomarker for poor prognosis in breast carcinoma”, Int J Mol Sci, vol. 23, n.º 7, art. 3754, 2022, doi: 10.3390/ijms230737.

X. Cheng, “A comprehensive review of HER2 in cancer biology and therapeutics”, Genes, vol. 15, n.º 7, art. 903, 2024, doi: 10.3390/genes15070903.

B. Rovcanin, S. Damjanovic, V. Zivaljevic, A. Diklic, M. Jovanovic y I. Paunovic, “The results of molecular genetic testing for RET pro-oncogene mutations in patients with medullary thyroid carcinoma in a referral center after the two-decade period”, Hippokratia, vol. 20, n.º 3, pp. 187-191, jul.-sept. 2016.

NIH. “Pruebas de marcadores tumorales más comunes”. Cancer.gov. [En línea]. Disponible: https://cancer.gov/espanol/cancer/diagnostico-estadificacion/diagnostico/lista-marcadores-tumorales

F. Rousseau, C. Lindsay, Y. Labelle y Y. Giguere, “Measuring the chronology of the translational process of molecular genetic discoveries”, Clin Chem Lab Med, vol. 57, n.º 8, pp. 1136-1141, 2019, doi: 10.1515/cclm-2018-1126.

Z. Jiang, H. Zhang, Y. Gao y Y. Sun, “Multi-omics strategies for biomarker discovery and application in personalized oncology”, Mol Biomed, vol. 6, art. 115, nov. 2025, doi: 10.1186/s43556-025-00340-0.

F. S. Ou, S. Michiels, Y. Shyr, A. A. Adjei y A. L. Oberg, “Biomarker discovery and validation: Statistical considerations”, J Thorac Oncol, vol. 16, n.º 4, pp. 537-545, abr. 2021, doi: 10.1016/j.jtho.2021.01.1616.

M. P. Pavlov, E. P. Diamandis y I. M. Blasuting, “The long journey of cancer biomarkers from the bench to the clinic”, Clin Chem, vol. 59, n.º 1, pp. 147-157, 2013, doi: 10.1373/clinche.2012.184614.

Published

2026-11-06

How to Cite

[1]
D. P. Armenta Calzadillas, M. Salcedo Vargas, and F. Jiménez Vega, “Cancer: Biomarkers, the Path from a Molecular Clue to Clinical Application”, Cult. Científ. y Tecnol., vol. 23, no. 3, pp. D1-D5, Nov. 2026.